No relation between CMV infection and mortality in the oldest old: results from the Belfrail study

Age and Ageing

Volumn 44, Issue 1, 2015, Pages 130-135

  Matheï, Catharina ^a,b   Adriaensen, Wim ^a,b   Vaes, Bert ^a,b   van Pottelbergh, Gijs ^a,b   Wallemacq, Pierre ^c   Degryse, Jan ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

80 and over; Aged; Cytomegalovirus; Mortality; Older people

Indexed keywords

IMMUNOGLOBULIN G; BIOLOGICAL MARKER; IMMUNOGLOBULIN E; VIRUS ANTIBODY;

AGED; AGING; ALL CAUSE MORTALITY; ARTICLE; BELGIUM; COHORT ANALYSIS; COMMUNITY DWELLING PERSON; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; VIRUS REACTIVATION; AGE; BLOOD; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPIDEMIOLOGY; IMMUNOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEROLOGY; TIME;

AGE FACTORS; AGED, 80 AND OVER; AGING; ANTIBODIES, VIRAL; BELGIUM; BIOLOGICAL MARKERS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEROLOGIC TESTS; TIME FACTORS;

EID: 84926472321     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/AGEING/AFU094     Document Type: Article

References (21)

1. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 2008; 197: 65-73.
2. Lubeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol 2010; 199: 53-60.
3. McVoy MA, Adler SP. Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals. J Infect Dis 1989; 160: 1-10.
4. Ji YN, An L, Zhan P, Chen XH. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 2012; 39: 6537-46.
5. Slots J. Herpesviral-bacterial synergy in the pathogenesis of human periodontitis. Curr Opin Infect Dis 2007; 20: 278-83.
6. Betjes MG, Litjens NH, Zietse R. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol Dial Transplant 2007; 22: 3298-303.
7. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis 2010; 16: 1620-7.
8. Ramos-Casals M, Cuadrado MJ, Alba P et al. Clinical guidelines for the management of acute viral infections in patients with systemic lupus erythematosus. Minerva Med 2009; 100: 437-46.
9. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009; 19: 47-56.
10. Wikby A, Ferguson F, Strindhall J et al. Immune risk phenotypes and associated parameters in very old humans: a review of findings in the Swedish NONA immune longitudinal study. In: Pawelec G, ed. Immunosenescence. New York: Landes Bioscience/Springer Medical Intelligence Unit, 2007; 1-14.
11. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 2011; 6: e16103.
12. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KTWareham NJ. Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of cancer-Norfolk cohort. Clin Infect Dis 2013; 56: 1421-7.
13. Vaes B, Pasquet A, Wallemacq P et al. The BELFRAIL (BFC80 +) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr 2010; 10: 39.
14. Burgess C, Perry K, Newham J, Kitchen A. Evaluation of Abbott Architect CMV IgG Assay Product code 6C152008, 2008.
15. Wang GC, Kao WH, Murakami P et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol 2010; 171: 1144-52.
16. Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA 2009; 301: 380-2.
17. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010; 172: 363-71.
18. Hadrup SR, Strindhall J, Køllgaard T et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006; 176: 2645-53.
19. Wang GC, Dash P, McCullers JA, Doherty PC, Thomas PG. T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med 2012; 4: 128ra42.
20. Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc 2005; 53: 747-54.
21. Mathei C, Vaes B, Wallemacq P, Degryse J. Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc 2011; 59: 2201-8.